doi:10.3969/j.issn.1673-8640.2023.012.018

Abstract

CLC Number:

R446.1

Figures/Tables 5

References 16

[1]	陈定宝, 张焕, 孔方舟, 等. 乳腺髓系肉瘤与弥漫性大B细胞淋巴瘤临床病理特征的比较[J]. 中华病理学杂志, 2020, 49(3):250-255.
[2]	王琳, 盛俊杰, 赵弘, 等. 淋巴细胞/单核细胞比值在弥漫大B细胞淋巴瘤患者预后中的意义[J]. 中华血液学杂志, 2019, 40(5):436-438.
[3]	中国抗癌协会血液肿瘤专业委员会, 中华医学会血液学分会白血病淋巴瘤学组, 中国临床肿瘤学会抗淋巴瘤联盟. 造血干细胞移植治疗淋巴瘤中国专家共识(2018版)[J]. 中华肿瘤杂志, 2018, 40(12):927-934.
[4]	许彭鹏, 赵维莅. 中国临床肿瘤学会淋巴瘤诊疗指南解读之弥漫性大B细胞淋巴瘤的规范治疗[J]. 华西医学, 2019, 34(4):351-354.
[5]	DEMIR A, DÜZGÖL M, BAYRAM N, et al. Ratio of monocytes to lymphocytes in peripheral blood in children diagnosed with active tuberculosis[J]. J Pediatr Res, 2020, 7(2):97-101. DOI URL
[6]	张胜楠. 动态监测外周血淋巴细胞与单核细胞比值对非霍奇金淋巴瘤患者的疗效判断和预后指导意义[D]. 郑州: 郑州大学, 2020.
[7]	吴晗, 张路, 张昀, 等. 伴自身抗体及噬血细胞综合征的弥漫性大B细胞淋巴瘤一例[J]. 中华全科医师杂志, 2019, 18(3):274-276.
[8]	郑立平, 沈未艾, 胡春东, 等. 血清CEA、CA19-9水平联合淋巴细胞绝对值对胰体尾癌患者的预后判断[J]. 中华胰腺病杂志, 2020, 20(6):465-468.
[9]	解婷, 徐凯, 韩翠平, 等. 18F-FDG PET/CT对弥漫性大B细胞淋巴瘤的预后价值[J]. 中国临床医学影像杂志, 2020, 31(5):350-353.
[10]	彭倩, 郭作隆, 廖洪, 等. 外周血淋巴细胞/单核细胞比值与急性脑梗塞的预后关系[J]. 中国卫生检验杂志, 2018, 28(3):309-312.
[11]	李小秋. 弥漫性大B细胞淋巴瘤的分子分型[J]. 中华病理学杂志, 2020, 49(10):993-995.
[12]	JIMENEZ-GALAN R, ABDEL-KADER-MARTIN L, TRUEBA M M, et al. 4CPS-187 prognostic value of haematological inflammatory markers in patients with metastatic non-small cell lung cancer treated with pembrolizumab[J]. Br Med J Publishing Group, 2020.
[13]	江亚军, 朱贵华, 何耀, 等. 弥漫大B细胞淋巴瘤患者外周血CD14-+单核细胞TF、VEGF表达的临床意义[J]. 中国实验血液学杂志, 2019, 27(1):67-73.
[14]	ANDRADE C M R, MONTES STARK L, ANTONIAZI MICHELIN M, et al. Interferon-alpha receptors and activation pathways in lymphocytes and monocytes in the peripheral blood of patients with cervical intraepithelial neoplasia or invasive cancer[J]. Eur J Gynaecol Oncol, 2018, 2:39.
[15]	蒋显勇, 申浩睿, 葛昌文, 等. 形态学在弥漫性大B细胞淋巴瘤骨髓侵犯诊断中的作用[J]. 中国实验血液学杂志, 2019, 27(2):421-425.
[16]	RAY-COQUARD I, CROPET C, VAN GLABBEKE M, et al. Lymphopenia as a prognostic factor for overall survival in advanced carcinomas,sarcomas,and lymphomas[J]. Cancer Res, 2009, 69(13):5383-5391. DOI URL

组别	例数	LYMPH#/ （×10⁹/L）	MO#/ （×10⁹/L）	LMR
DLBCL组	60	2.12±0.78	0.36±0.12	6.64±2.28
侵袭性淋巴瘤组	60	2.14±0.56	0.31±0.09	7.11±2.05^*
正常对照组	60	2.16±0.82	0.28±0.21	8.57±3.52^*
统计值		0.485	2.562	3.509
P值		0.689	0.012	0.001

组别	例数	LYMPH#/ （×10⁹/L）	MO#/ （×10⁹/L）	LMR
DLBCL组	60	2.12±0.78	0.36±0.12	6.64±2.28
侵袭性淋巴瘤组	60	2.14±0.56	0.31±0.09	7.11±2.05^*
正常对照组	60	2.16±0.82	0.28±0.21	8.57±3.52^*
统计值		0.485	2.562	3.509
P值		0.689	0.012	0.001

组别	例数	性别		IPI评分		临床分期		症状		LDH		ECOG
组别	例数	男性	女性	0~2分	3~5分	Ⅰ~Ⅱ期	Ⅲ~Ⅵ期	有	无	升高	正常	0~1分	2~5分
LYMPH#≥1.0×10⁹/L组	35	21	14	25	10	20	15	9	26	10	25	24	11
LYMPH#<1.0×10⁹/L组	25	14	11	5	20	7	18	19	6	19	6	7	8
χ²值		0.096		15.429		5.004		14.816		13.137		9.163
P值		0.757		<0.001		0.025		<0.001		<0.001		0.002

组别	例数	性别		IPI评分		临床分期		症状		LDH		ECOG
组别	例数	男性	女性	0~2分	3~5分	Ⅰ~Ⅱ期	Ⅲ~Ⅵ期	有	无	升高	正常	0~1分	2~5分
LYMPH#≥1.0×10⁹/L组	35	21	14	25	10	20	15	9	26	10	25	24	11
LYMPH#<1.0×10⁹/L组	25	14	11	5	20	7	18	19	6	19	6	7	8
χ²值		0.096		15.429		5.004		14.816		13.137		9.163
P值		0.757		<0.001		0.025		<0.001		<0.001		0.002

组别	例数	性别		IPI评分		临床分期		症状		LDH		ECOG
组别	例数	男性	女性	0~2分	3~5分	Ⅰ~Ⅱ期	Ⅲ~Ⅵ期	有	无	升高	正常	0~1分	2~5分
MO#≥0.5×10⁹/L组	31	20	11	20	11	15	16	10	21	5	26	22	9
MO#<0.5×10⁹/L组	29	15	14	7	22	6	23	24	5	15	14	8	21
χ²值		1.009		9.870		5.050		15.562		8.543		11.279
P值		0.315		0.002		0.025		<0.001		0.003		0.001

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 5

References 16

Related Articles 15

Recommended Articles

Metrics

变量	P值	风险比	95%可信区间
年龄	0.002	12.262	7.262~27.263
性别	0.452	2.325	1.125~4.893
临床分期	0.235	1.521	0.528~2.553
IPI评分	0.002	8.214	3.268~15.262
临床症状	0.165	1.236	0.852~2.936
LDH水平	0.103	0.339	0.152~0.775
ECOG	0.002	4.412	2.172~8.362
LYMPH#	0.049	2.262	0.862~6.825
MO#	0.012	3.655	1.315~9.571
LMR	0.310	0.457	0.123~1.893

[1]	DUAN Pengcang, DONG Ruifang, LIU Xiaoman, CAO Yang, WANG Ruoxi. Correlation between serum Trx2，P-tau and total magnetic resonance imaging load score and cognitive function in patients with cerebral small vessel disease [J]. Laboratory Medicine, 2024, 39(1): 1-6.
[2]	ZHANG Miaomiao, DUAN Dongkui, YU Chun, WANG Lina. Expression and prognostic assessment value of miR-924 and SLC1A5 in lung cancer tissues [J]. Laboratory Medicine, 2024, 39(1): 13-18.
[3]	ZHANG Yang, ZHANG Dehe, TANG Shiyue, ZHANG Jun, WANG Jianming, CHEN Ling. Predictive value of soluble CD163 combined with Charlson index for esophageal variceal bleeding in patients with liver cirrhosis [J]. Laboratory Medicine, 2024, 39(1): 19-25.
[4]	LIU Bohan, LIU Yiwen, HE Yiqing, LU Renquan, DU Yan, ZHANG Guoliang, GUO Qian, GAO Feng, YANG Cuixia. Serum amphiregulin and mesothelin in auxiliary diagnosis of breast cancer [J]. Laboratory Medicine, 2024, 39(1): 26-30.
[5]	LAI Yuanyuan, HE Zhenye, SHEN Huaqing, LIN Yiteng, LIU Xijun, QI Jun, LIN Yongping. Roles of TAT，PIC and thromboelastography for assessing coagulation function in tumor patients [J]. Laboratory Medicine, 2024, 39(1): 43-46.
[6]	ZHANG Xiaoling, JIN Yao, LI Sufang, PENG Haiying. Synergistic diagnosis of THR mRNA and ALCAT1 in hyperthyroidism heart disease [J]. Laboratory Medicine, 2024, 39(1): 60-67.
[7]	. [J]. Laboratory Medicine, 2024, 39(1): 68-70.
[8]	LAN Jun, LU Shuting, YANG Jianrui. Roles of serum IL-26 and IL-27 levels in patients with colorectal cancer [J]. Laboratory Medicine, 2024, 39(1): 7-12.
[9]	JIANG Haoqin, XU Qianqian, XU Liming, GUAN Ming. Homogenization management and practice of clinical blood and body fluid determinations [J]. Laboratory Medicine, 2024, 39(1): 95-99.
[10]	FAN Lieying. Research status and application prospects of biomarkers for membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1111-1114.
[11]	SUN Lincheng, LI Jianfeng, CHENG Weili, JI Panyun. Roles of anti-PLA2R IgG4 antibody and PLA2R IgG4/IgG ratio in primary membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1115-1120.
[12]	LIU Qingyang, YUAN Jianming, XIA Jinjun, JIANG Fengying, WANG Qiubo, WANG Xiaoming. CXCL9 as a potential diagnostic marker of rheumatoid arthritis based on GEO database and experimental verification [J]. Laboratory Medicine, 2023, 38(12): 1121-1129.
[13]	YANG Xiao, LI Enling, WU Lixia, DAI Yingxin, WANG Zhiqing, HUANG Hao, ZHENG Bing. Influence of cytoplasmic antinuclear antibody on indirect immunofluorescence assay based antineutrophil cytoplasmic antibody determination [J]. Laboratory Medicine, 2023, 38(12): 1135-1140.
[14]	XIANG Jin, LIU Aiping, HU Yao, WU Zhiyuan, CAO Guojun, GUAN Ming. ANA profiles in COVID-19 patients and influence of serum heat-inactivation on ANA determination [J]. Laboratory Medicine, 2023, 38(12): 1141-1146.
[15]	CHENG Yu, XU Zhen, LU Liu, DING Menglei, YU Shanshan, ZONG Ming, FAN Lieying. Expression and risk factors of anti-ACE-2 antibody in serum of patients with COVID-19 [J]. Laboratory Medicine, 2023, 38(12): 1147-1152.